WATCH: Capricor Therapeutics – CAP-1002 HOPE-3 Program Update (Webinar Recording)
PPMD and Capricor Therapeutics held a community webinar on October 25, 2023 to provide an overview of the latest regulatory developments for Capricor’s ongoing HOPE-3 Phase 3 study of CAP-1002, the company’s cell therapy. Capricor’s…Learn More